The Chronic Fatigue Syndrome (Myalgic Encephalomyelitis) drugs in development market research report provides comprehensive information on the therapeutics under development for Chronic Fatigue Syndrome (Myalgic Encephalomyelitis), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Chronic Fatigue Syndrome (Myalgic Encephalomyelitis). Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Chronic Fatigue Syndrome (Myalgic Encephalomyelitis) and features dormant and discontinued products.
GlobalData tracks 11 drugs in development for Chronic Fatigue Syndrome (Myalgic Encephalomyelitis) by 11 companies/universities/institutes. The top development phase for Chronic Fatigue Syndrome (Myalgic Encephalomyelitis) is phase i with three drugs in that stage. The Chronic Fatigue Syndrome (Myalgic Encephalomyelitis) pipeline has 11 drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Chronic Fatigue Syndrome (Myalgic Encephalomyelitis) pipeline products market are: AIM ImmunoTech, Virios Therapeutics and Biovista.
The key targets in the Chronic Fatigue Syndrome (Myalgic Encephalomyelitis) pipeline products market include Toll Like Receptor 3, Soluble Guanylate Cyclase, and Sodium Dependent Dopamine Transporter.
The key mechanisms of action in the Chronic Fatigue Syndrome (Myalgic Encephalomyelitis) pipeline product include Alpha 1 Adrenergic Receptor Agonist with one drug in Preclinical. The Chronic Fatigue Syndrome (Myalgic Encephalomyelitis) pipeline products include seven routes of administration with the top ROA being Intraperitoneal and four key molecule types in the Chronic Fatigue Syndrome (Myalgic Encephalomyelitis) pipeline products market including Small Molecule, and Oncolytic Virus.
Chronic Fatigue Syndrome (Myalgic Encephalomyelitis) overview
Chronic Fatigue Syndrome (CFS) or Myalgic Encephalomyelitis (ME) is a chronic condition causing fatigue and malaise which worsens with underlying diseases of cognitive dysfunction, immune dysfunction, unrefreshing sleep, pain, autonomic dysfunction, neuroendocrine and immune symptoms. The cause of this condition is unpredictable, but the symptoms can vary and are unpredictable. Fatigue or tiredness, extreme pain or discomfort, insomnia or sleep disturbance, pain in muscles, fever, and headache is seen. There are no exact diagnostic tests for this condition. If necessary, blood tests or radiographic findings are done. Treatment is symptomatic and non-pharmacological ways of taking rest, reducing risky activities, energy supplements.
For a complete picture of Chronic Fatigue Syndrome (Myalgic Encephalomyelitis)’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
